Plain-English translation of NCT07491497 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new oral medication called in people with advanced lung cancer that has a specific genetic change called an ALK mutation. The study will first figure out the right dose and then test how well the medication works, especially for people whose cancer has stopped responding to other ALK-targeting treatments they've already tried.
Many people with ALK-positive lung cancer eventually develop resistance to standard treatments, meaning their current medications stop working. This trial exists to find out whether this new medication can help people whose cancer has become resistant to other therapies.
You likely qualify if…
You likely don't qualify if…
You would take the oral medication by mouth, likely daily. The study has two parts: the first part focuses on finding the right dose, and the second part tests how well the medication works in different groups of patients based on their previous treatments. You would have regular visits for blood tests, imaging scans, and check-ins with the study team to monitor how you are responding and watch for any side effects.
AI-generated summary from trial data · Sep 19, 2026 · Not medical advice
United States